Sociedad Americana de Hirudoterapia

Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos

CECMED · Cuba · latin america

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Cuba's Centre for State Control of Medicines and Medical Devices — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national medical device framework or traditional and natural medicine pathways as appropriate.

Regulatory Profile

Agency type
national regulator
Region
latin america
Country
Cuba
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Cuban national medical device and medicines law
  • Cuban framework for medicina natural y tradicional (MNT) as appropriate

Prescriber Requirements

  • Cuban-licensed physician (médico) under Ministry of Public Health authority — order required for any biomedical device application
  • Practitioners of medicina natural y tradicional may have separate scope under Cuban national law; specific hirudotherapy authorisation not independently verified by ASH

Supply Chain & GMP

CECMED registration as applicable; Spanish-language labelling. Standard cold-chain conditions.

Import/Export Rules

CECMED import licence requirements; veterinary clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Cuba has formally integrated medicina natural y tradicional (MNT) into its national health system; whether hirudotherapy is recognised within MNT or under CECMED's device pathway has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.